Fig. 6: Relationship between pre-challenge anti-PfCSP antibody titers and protection from challenge. | npj Vaccines

Fig. 6: Relationship between pre-challenge anti-PfCSP antibody titers and protection from challenge.

From: Needle-free, spirulina-produced Plasmodium falciparum circumsporozoite vaccination provides sterile protection against pre-erythrocytic malaria in mice

Fig. 6

a Vaccine Efficacy (VE) was calculated for each group as 1 – risk ratio (×100) and plotted against respective mean endpoint titer. b The percentage of mice that were blood smear negative post-challenge was plotted against the respective mean NANP-specific IgG endpoint titer at the time of challenge. For A and B for all groups except where indicated, challenge took place on day 70 of the respective trial. In a–b, each data point represents a group of mice as shown in the inset key (n = 5 mice/group unless otherwise indicated). c Individual mouse NANP-specific IgG endpoint titers at the time of challenge were plotted compared to the challenge outcomes. Each data point represents an individual mouse with the corresponding groups identified in the inset key.

Back to article page